TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07684820: To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment

Sponsor: Expedition Therapeutics, Inc · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 600 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,519,200

Rescue Site Savings

+$2,324,000

Unlock Full NCT07684820 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07684820 Rescue Dossier →